Top Featured

The Clinical Trial Supply Forum (13-15 May, 2025 in Brussels, Belgium) is a platform where Clinical Trial Supply professionals on all seniority levels gather to exchange exclusive insights, establish valuable connections and collaboratively tackle industry challenges. 

Are you interested in seeing who you will meet at Clinical Trial Supply Forum 2025? Download our current attendee list today.

Join us to collaborate with senior industry leaders to successfully build a supply chain that is agile, sustainable and built around patient needs. 

Are you wondering who you will meet at the event? Download our Sample 2025 attendee list and find out.

Are you interested in sponsoring Clinical Trial Supply Forum 2025? Download our 2025 prospectus and see how you can be a part of our event. We have a variety of flexible sponsorship packages, designed to align with your unique goals.

Sustainability is no longer a choice, it’s a necessity in clinical trial supply chains. With increasing regulations, growing environmental responsibilities, and the push for more efficient, patient-centric operations, it’s time to take action. The Sustainability Improvement To-Do List is your clear, step-by-step guide to integrating sustainability into every stage of your supply chain, with a regional breakdown of sustainability initiatives across the EU, UK, and US.

Download to learn more about:

• Carbon Footprint Assessment: Measure emissions across production, transportation, and energy use to pinpoint areas for improvement.
• Carbon Offsetting Strategies: Balance unavoidable emissions through renewable energy investments and reforestation initiatives.
• Energy Efficiency Upgrades: Optimise machinery, reduce waste, and implement energy-saving technologies.
• Sustainable Transport Solutions: Lower emissions with low-emission vehicles, optimised delivery routes, and shipment consolidation.

Sustainability isn’t just about compliance, it’s about future-proofing your supply chain and this infographic gives you clear, practical steps to meet evolving sustainability regulations across regions, reduce environmental impact while increasing operational efficiency, and ensure a resilient, patient-focused supply chain. 

Alexandra Tsioni, Associate Director, Clinical Supply Chain Global Lead, Israel, brilliantly presented a 'Direct-to-Patient Case Study' at the Clinical Trial Supply Forum 2022. 

Download your copy to learn more about: 

• The impact of COVID-19 on clinical trials 
• Direct-to-patient vs traditional approaches 
• The impact on clinical supplies 
• Direct-to-patient case study considerations, challenges and mitigations

Building reverse logistics and product reconciliations into your supply strategy to optimise end to end distribution management was delivered at the Clinical Trial Supply Forum 2022 by Kamal Amin, Head of Supply Management, Galderma.

Download your copy to view:

• The role of clinical supplies teams within the reverse logistics and reconciliations management strategy 
• Where your returns and reconciliations fit into your end-to-end clinical supply lifecycle
• Ways to reduce unforeseen costs through flexible product return and destruction strategies 
• End-to-end alignment in supply management by effectively engaging your clinical teams across the process implementation lifecycle 

In the realm of clinical trials, patient recruitment poses a significant challenge, with merely 2%-5% of U.S. patients currently engaged in these crucial research endeavors. Patients represent the cornerstone of any clinical trial, without whom progress in developing novel therapies and advancing care innovation would stall. Consequently, ensuring patient participation and completion stands as a primary focus for clinical trial sponsors. While extensive research has been dedicated to understanding barriers to participation, such as access and indirect expenses like travel and lodging, another critical factor hindering participation and exacerbating patient drop-out emerges: the coverage of care for baseline or comparator drugs in the U.S., which contrasts with other countries like the U.K. where sponsors typically bear such costs. This disparity in coverage may disproportionately impact socio-economically vulnerable and diverse patient populations, potentially impeding their access to and engagement in vital clinical trials.

Dive into the whitepaper today to explore:

• The current state of care coverage in cancer trials
• Developing a framework to understand sponsor coverage impact
• Cost of noncoverage versus cost of coverage
• A case for coverage